TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Avastin treatment discontinuation due to Avastin-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Fall History
Endpoint domain: Adverse events/effects
Primary endpoint: non-surgical rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Grade 2 or Higher Hand-Foot Skin Reaction (HFSR) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: All Grade Hand-Foot Skin Reaction (HFSR) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of SB-656933
Endpoint domain: Adverse events/effects
Primary endpoint: Best corrected near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary NAG secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Infant neuro-development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Headache Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent and child-reported evening settling difficulties
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Corneal Staining change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of teeth with apex closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of at least one RBC transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in degeneration of the optic nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genotype of HTIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of glottic opening (POGO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal gap distance filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Direct Behavior Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Change in Frequency of Migraine Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic rate of lung biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Homeostatic model assessment-insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of endoscopic ultrasonography and percutaneous trans-hepatic biliary drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic control response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in ear blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Score of XO test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Decayed, Missing, or Filled Teeth or Surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with Early Childhood Caries Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of solifenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of solifenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of solifenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of mirabegron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG-EMG coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average Percent Change in TRAP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Endotracheal tube intracuff pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD14/CD16-Monocyte-Subsets Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Unsolicited Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: change in Knee and Osteoarthritis Outcome Score for Children
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activated Clotting Time (ACT) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite of Death, Myocardial Infarction, and Urgent Revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: Major Bleeding Events During Hospital Stay
Endpoint domain: Adverse events/effects
Primary endpoint: urinary tract infections rate
Endpoint domain: Adverse events/effects
Primary endpoint: MTD or RP2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Glucose Reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with sleep disorder
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: MMP and TIMP mRNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proportion of nights with successful treatment of RLS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol use disorder identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug use disorder identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Outcome for and after PBM program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C24hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak trough ratio (PTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of therapeutic monitoring measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASAS20 Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average office blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic sensitivity of OctreoScan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of ACC-DBS: success of the process of surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Feasibility of ACC-DBS: neurological success of the process of chronic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Feasibility of ACC-DBS: psychiatric success of the process of chronic stimulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feasibility of ACC-DBS: cognitive success of the process of chronic stimulation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relative presence of primary mutation and resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of the small molecule kinase inhibitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade ≥3 early GU toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ≥3 early GI toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Viral load increase over 20,000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Annual Overall Skeletal Morbidity Rate (SMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of plasma eicosanoid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of occurrence of second immune-related adverse events (irAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in the Gingival Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the Gingival Bleeding Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the Microbiological analysis of saliva for oral streptococcus count evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal neuropathy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Preference for Nasal Spray
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Food Benefits Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in patient complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with global improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence rate of bleeding or thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Proliferation of Hyalocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Rate at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 25 hydroxy vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cardiac output value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of FRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in traumatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported well-being during recent birth
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the overall perception of birth experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under time curve (AUC) of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pharmacokinetics of isofagomine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of NTBI after an oral iron load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure ulcer stage assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to symptomatic skeletal event (SSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of the animated home-based physical exercise program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lesions needed to achieve modification of slow AV nodal pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with no renal toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants with Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in number of urge urinary incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Physician diagnosed asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hepatitis C virus (HCV) incidence
Endpoint domain: Mortality/survival
Primary endpoint: Standard Base Excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Total Patient Satisfaction and Preference Questionnaire (PASAPQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetic data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: severity of acute postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gametocyte prevalence and density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Adherent to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of hospitals providing postoperative monitoring of epidural analgesia
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: PTINR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetic parameters (Cmax, Tmax, AUC, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substance Use Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of full-field cone electroretinogram amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MPR on CMR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Lesions Cleared Histologically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major adverse cardiac and cerebrovascular events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from individual adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time to NMOSD Attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of survival at M12
Endpoint domain: Mortality/survival
Primary endpoint: Change in Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Courses of antibiotics needed after delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: serum quantitative D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Hepatic Venous Pressure Gradient (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-Free Survival (EFS) Using Kaplan-Meier
Endpoint domain: Mortality/survival
Primary endpoint: Time to Reach the Maximum Plasma Concentration of TMC207
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration of TMC207
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve From Time of Administration up to 72 Hours Post Dosing of TMC207
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nurses' knowledge and attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kessler Psychological Distress Scale (K10)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of ventilator associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity at Day 30
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With ≥4 Fold Rise in Serotype-specific OPA for 2 Unique V114 Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of granuloma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: INR time percentage in the target zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analogue Scale for Pain (VAS-P) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of a positive 18F-Flutemetamol scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Peripheral Arterial Tonometry (PAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dose Limiting Toxicity (DLT) rate
Endpoint domain: Adverse events/effects
Primary endpoint: LDL cholesterolemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chest Pain Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of using the ClinMACS CD25 Reagent device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CD25+ Treg depleted DLI
Endpoint domain: Adverse events/effects
Primary endpoint: White matter mean diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes From Baseline in HIV-1 Reservoir (Total HIV-1DNA; Integrated HIV-1 DNA in Unfractionated CD4+ T Cells and Replication Competent Provirus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression of joint space size and volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: durability of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amounts of metabolites in uterine cervical tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival at 1 Year Post UCBT
Endpoint domain: Mortality/survival
Primary endpoint: Marginal Bone Level Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Static Physician's Global Assessment Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Score Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating disorder diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, seriousness and intensity of Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in physical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vital signs - blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-Hospital resuscitation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-technical skills assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central nerve system duration of response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy, sensitivity, and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional transcranial doppler measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chronic significant post operative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Haemoglobin status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With Plasma HIV RNA < 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroma quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: discriminatory value of MRI ADC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discriminatory value of MRI D value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge improvement regarding ESRD treatment options
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Shared decision-making between patients and physicians
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Appetite loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (QL2)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Short-term graft failure
Endpoint domain: Mortality/survival
Primary endpoint: clinical manifestations of pulmonary cryptococcosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HPV DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation ratio of host cell gene marker panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of effect of injected H.A.
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Aneurysm Rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes